Who are Cathflo Activase (Alteplase)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Activase, Trasylol, Cyklokapron, Amicar, Tranexamic acid + Standard of Care, Tenecteplase thrombolysis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cathflo-activase-alteplase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cathflo Activase (Alteplase) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cathflo Activase (Alteplase) (Cathflo Activase (Alteplase)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Tissue plasminogen activator (tPA). Area: Cardiovascular / Interventional.

marketed Fibrinolytic agent / Tissue plasminogen activator (tPA) Plasminogen Cardiovascular / Interventional Small molecule Live · refreshed every 30 min

Target snapshot

Cathflo Activase (Alteplase) (Cathflo Activase (Alteplase)) — Genentech, Inc.. Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cathflo Activase (Alteplase) TARGET	Cathflo Activase (Alteplase)	Genentech, Inc.	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen
Activase	ALTEPLASE	Roche	marketed		Plasminogen	1996-01-01
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic acid + Standard of Care	Tranexamic acid + Standard of Care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tenecteplase thrombolysis	Tenecteplase thrombolysis	Xuanwu Hospital, Beijing	marketed	Fibrinolytic agent / Thrombolytic	Fibrin; Plasminogen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Tissue plasminogen activator (tPA) class)

Central Hospital, Nancy, France · 1 drug in this class
Genentech, Inc. · 1 drug in this class
Hospital Clinic of Barcelona · 1 drug in this class
NHS Greater Glasgow and Clyde · 1 drug in this class
Southwest Hospital, China · 1 drug in this class
The George Institute · 1 drug in this class
University of Manitoba · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cathflo Activase (Alteplase) — Competitive Intelligence Brief. https://druglandscape.com/ci/cathflo-activase-alteplase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab